ArticleFrontiers in oncology2026
Case Report: Autologous stem cell transplantation in a patient diagnosed with AL amyloidosis in Kazakhstan.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: AL amyloidosis is a rare plasma cell disorder that causes progressive organ dysfunction due to extracellular deposition of misfolded immunoglobulin light chains. Reports from Central Asia are scarce, and there is limited documentation of successful integration of daratumumab-based therapy with autologous hematopoietic stem cell transplantation (auto-HSCT) in this region. Case presentation: A 65-year-old woman presented with progressive left supraclavicular lymphadenopathy. Examination revealed bilateral cervical and supraclavicular lymphadenopathy with an ECOG performance status of 1. Laboratory testing showed elevated κ free light chains (50.96 mg/L; κ/λ ratio 12.0). Lymph node biopsy with Congo red staining revealed amyloid deposits with apple-green birefringence, and immunohistochemical protein typing confirmed AL amyloidosis type kappa. Interventions and outcomes: The patient received four cycles of bortezomib-cyclophosphamide-dexamethasone without hematologic response, followed by two cycles of daratumumab-cyclophosphamide-bortezomib-dexamethasone, achieving a very good partial response (dFLC reduced from 46.7 to 11.9 mg/L) and renal recovery (GFR from 21 to 71 mL/min). She underwent high-dose melphalan conditioning and auto-HSCT, with neutrophil engraftment on day +19 and grade 3 mucositis as the main complication. At one-year follow-up, she remains in hematologic and organ remission on monthly daratumumab maintenance. Conclusion: This case was selected for reporting due to several distinctive clinical and organizational aspects. AL amyloidosis remains underdiagnosed in Central Asia, and experience with daratumumab-based regimens combined with autologous hematopoietic stem cell transplantation (auto-HSCT) is limited in this region. At our center, patients with suspected plasma cell dyscrasias frequently present with advanced or atypical disease manifestations, often leading to diagnostic delays. Compared with other AL amyloidosis cases treated at our institution, this patient demonstrated an uncommon presentation dominated by extensive extramedullary lymph node involvement, absence of overt cardiac manifestations, and prolonged diagnostic latency. Furthermore, the case illustrates the feasibility of integrating modern induction therapy with daratumumab, successful stem cell mobilization, and auto-HSCT in a resource-variable healthcare setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.